Skip to main content

Table 2 Companion PD-L1 Assays in Development for PD-1/PD-L1 Inhibitors

From: PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

Drug

Drug target

Companion antibody clone

Developer

Definition of positive test

Nivolumab

PD-1

28-8

Dako

≥5 % membranous staining of tumor cells (minimum 100 cells evaluated)

Bristol-Meyers Squibb

Pembrolizumab

PD-1

22C3

Dako

≥1%a membranous staining of tumor cells or immune cells that are intercalating or at the tumor interface

Merck

Atezolizumab (MPDL3280A)

PD-L1

SP142

Ventana

Each specimen assigned a score based on both tumor and immune cell PD-L1:

Genentech/Roche

TC3/IC3 PD-L1 ≥ 50 %

TC2/IC2 PD-L1 5-49 %

TC1/IC1 PD-L1 1-4 %

TC0/IC0 PD-L1 < 1 %

Durvalumab (MEDI4736)

PD-L1

SP263

Ventana

≥25 % membranous staining of tumor cells

MedImmune/AstraZeneca

  1. aThe FDA indication in NSCLC for pembrolizumab requires PS ≥50 %